The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | The Alexander study: AUTO3 with pembrolizumab for R/R DLBCL patients
Aravind Ramakrishnan, MD, BSc, Sarah Cannon Blood Cancer Center at St. David’s South Austin Medical Center, Austin, TX, discusses the results of Alexander (NCT03287817), a Phase I study aiming to evaluate the efficacy and safety of AUTO3, a novel CD19/22 dual targeting CAR-T cell therapy, with pembrolizumab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research grants: Autolous, Incyte, Kadmon Pharmaceuticals, Kite Pharma, Novartis, Shire Development, Mana Therapeutics, Alpine Immune Sciences, Allovir.
All payments made to institution.
